Please assess the completion status of the following clinical trial:

Trial Title: COVidIVERmectin: Ivermectin for Treatment of Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years~* Positivity at RT-PCR per SARS_CoV2 (nasopharyngeal swabs)~* Consent to participation to the study and to the processing of personal data~* COVID-19 Severity Score \< 3~* Patient able to take oral drugs~Exclusion Criteria:~* Pregnant or lactating women (pregnancy test not required, if doubt patient is excluded)~* Subjects suffering from known CNS diseases~* Lack of (or inability to provide) informed consent~* Patient under dialysis~* Any severe medical condition with a prognosis of \< 6 months~* Patients under warfarin treatment~* Patients under antiviral treatment~* Patients under chloroquine phosphate or hydroxychloroquine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I_600 (Type: EXPERIMENTAL): ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
- I_1200 (Type: EXPERIMENTAL): ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).